News & more

Reading Room

  • Kasran, A., et al., Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther, 2005. 22(2): p. 111-22.
  • Boon, L., et al., Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses. J Immunol, 2001. 167(5): p. 2942-9.
  • t Hart, B.A., et al., Treatment with chimeric anti-human CD40 antibody suppresses MRI-detectable inflammation and enlargement of pre-existing brain lesions in common marmosets affected by MOG-induced EAE. J Neuroimmunol, 2005. 163(1-2): p. 31-9.
  • Haanstra, K.G., et al., Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation, 2003. 75(5): p. 637-43. Haanstra, K.G., et al., Costimulation blockade followed by a 12-week period of cyclosporine A facilitates prolonged drug-free survival of rhesus monkey kidney allografts. Transplantation, 2005. 79(11): p. 1623-6.
  • de Vos, A.F., et al., Antagonist anti-human CD40 antibody inhibits germinal center formation in cynomolgus monkeys. Eur J Immunol, 2004. 34(12): p. 3446-55.
  • Alabraba, E.B., et al., Coculture of human liver macrophages and cholangiocytes leads to CD40-dependent apoptosis and cytokine secretion. Hepatology, 2008. 47(2): p. 552-62.
  • Peters, A.L, Stunz, L.L., Bishop, G.A. CD40 and autoimmunity: the dark side of a great activator. Semin Immunol, 2009. 21(5): p. 293-300.